Jerald Insel, MD
Cardiovascular Disease · Nottingham, MDNPI 1871561043
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,782 of the $29,244 with a category attached, or 74.5%. 37 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 50.9% of the total. Reporting peaked in 2019 at $15,442 and has fallen 95.1% since, to $756 in 2025. Among cardiovascular disease clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $96.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15K
- Sanofi-aventis U.S. LLC$8K
- Regeneron Healthcare Solutions, Inc.$1K
- Novartis$910
- Abiomed$734
- Boehringer Ingelheim$494
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$21,78274%
- Travel & lodging$1,9337%
- Food & beverage$5,37218%
- Education$1571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 40 | $14,884 |
| Sanofi-aventis U.S. LLC | 17 | $7,921 |
| Regeneron Healthcare Solutions, Inc. | 3 | $1,290 |
| Novartis | 68 | $910 |
| Abiomed | 1 | $734 |
| Boehringer Ingelheim | 24 | $494 |
| Kowa Pharmaceuticals America, Inc. | 25 | $487 |
| Amgen | 19 | $329 |
| AstraZeneca | 8 | $268 |
| Scpharmaceuticals Inc. | 12 | $242 |
| Pfizer | 12 | $234 |
| Merck | 13 | $198 |
| Medtronic | 3 | $175 |
| Johnson & Johnson | 13 | $155 |
| Atricure, Inc. | 1 | $112 |
| E.r. Squibb & Sons, L.L.C. | 7 | $109 |
| Abbott | 2 | $87 |
| Amarin Pharma, Inc. | 5 | $86 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| Philips North America LLC | 3 | $50 |
| Astellas Pharma US Inc | 2 | $49 |
| Gilead | 3 | $45 |
| Braemar Manufacturing, LLC | 1 | $36 |
| Corcept Therapeutics | 1 | $33 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Vifor Pharma, Inc. | 2 | $28 |
| GRT US Holding, Inc. | 2 | $27 |
| Exact Sciences | 1 | $18 |
| Mannkind Corporation | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Averitas Pharma Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $14 |
| Bayer | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$14,202
- PRALUENT$8,879
- Impella$734
- 3F$129
- ATRICLIP LAA EXCLUSION SYSTEM$112
How this compares
$29,244 in reported general payments places this provider in the 90th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 299 | $375,737 |
| FuroscixFurosemide | 13 | $93,132 |
| Repatha SureclickEvolocumab | 90 | $92,242 |
| XareltoRivaroxaban | 59 | $76,870 |
| EntrestoSacubitril/Valsartan | 42 | $55,618 |
| JardianceEmpagliflozin | 36 | $33,410 |
| BrilintaTicagrelor | 36 | $25,651 |
| VascepaIcosapent Ethyl | 52 | $22,452 |
| Praluent PenAlirocumab | 20 | $16,725 |
| Nitroglycerin PatchNitroglycerin | 242 | $15,347 |
| EdarbiAzilsartan Medoxomil | 27 | $12,802 |
| Rosuvastatin Calcium | 283 | $7,565 |
| Ranolazine ErRanolazine | 94 | $6,758 |
| Amiodarone Hcl | 111 | $5,261 |
| Icosapent Ethyl | 20 | $5,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $234 | $375,737299 claims |
| Scpharmaceuticals Inc.Furoscix | $242 | $93,13213 claims |
| Johnson & JohnsonXarelto | $155 | $76,87059 claims |
| NovartisEntresto | $910 | $55,61842 claims |
| Boehringer IngelheimJardiance | $494 | $33,41036 claims |
| AstraZenecaBrilinta | $268 | $25,65136 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $11 | $12,80227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Nottingham
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Mark HaigneyBethesda$121K
- Charles CummingsBaltimore$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.